Amyloidosis prognosis is often related to the onset of heart failure and a 
worsening that is concomitant with kidney-liver dysfunction; thus the Model for 
End-stage Liver disease (MELD) may be an ideal instrument to summarize 
renal-liver function. Our aim has been to test the MELD score as a prognostic 
tool in amyloidosis. We evaluated 128 patients, 46 with TTR-related amyloidosis 
and 82 with AL amyloidosis. All patients had a complete clinical and 
echocardiography evaluation; overall biohumoral assessment included troponin I, 
NT-proBNP, creatinine, total bilirubin and INR ratio. The study population was 
dichotomized at the 12 cut-off level of MELD scores; those with MELD score >12 
had a lower survival compared to controls in the study cohort (40.7 vs 66.3 %; 
p = 0.006). Either as a continuous and dichotomized variable, MELD shows its 
independent prognostic value at multivariable analysis (HR = 1.199, 95 % CI 
1.082-1.329; HR = 2.707, 95 % CI 1.075-6.817, respectively). MELD shows a lower 
prognostic sensitivity/specificity ratio than troponin I and NT-proBNP in the 
whole study population and AL subgroup, while in TTR patients MELD has a higher 
sensitivity/specificity ratio compared to troponin and NT-proBNP (ROC 
analysis-AUC: 0.853 vs 0.726 vs 0.659). MELD is able to predict prognosis in 
amyloidosis. A MELD score >12 selects a subgroup of patients with a higher risk 
of death. The predictive accuracy seems to be more evident in TTR patients in 
whom currently no effective scoring systems have been validated.